RandomizedclinicaltrialoflovastatininHIV-infected, HAART na€ive patients (NCT00721305)

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

  2012cited by this paper
• Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients

  2011cited by this paper
• High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial.

  2011cited by this paper
• Statins as anti-inflammatory therapy in HIV disease?

  2011cited by this paper
• Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems

  2010cited by this paper
• The Role of Lipids in Retrovirus Replication

  2010cited by this paper
• Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study.

  2010cited by this paper
• Regulation of different inflammatory diseases by impacting the mevalonate pathway

  2009cited by this paper
• Emerging concepts in the immunopathogenesis of AIDS.

  2009cited by this paper
• LFA-1 Antagonists as Agents Limiting Human Immunodeficiency Virus Type 1 Infection and Transmission and Potentiating the Effect of the Fusion Inhibitor T-20

  2009cited by this paper
• Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial

  2009cited by this paper
• Failure of atorvastatin to modulate CSF HIV-1 infection

  2008cited by this paper
• Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication.

  2008cited by this paper
• Statins and sepsis.

  2008cited by this paper
• Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.

  2008cited by this paper
• Statins Disrupt CCR5 and RANTES Expression Levels in CD4+ T Lymphocytes In Vitro and Preferentially Decrease Infection of R5 Versus X4 HIV-1

  2007cited by this paper
• Validity of four indirect methods to measure adherence in primary care hypertensives

  2007cited by this paper
• Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART

  2007cited by this paper
• The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy

  2006cited by this paper
• Long-term statin use does not act on the temporal trend of CD4 cell count in patients on virologically effective HAART

  2006cited by this paper
• The potential utility of statin vaginal gels in the prevention of HIV transmission.

  2005cited by this paper
• Statins Could Be Used to Control Replication of Some Viruses, Including HIV-1

  2005cited by this paper
• Evaluation of the anti-HIV activity of statins

  2005cited by this paper
• The Effect of Statins on HIV Rebound and Blips

  2005cited by this paper
• Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy.

  2005cited by this paper
• Statins Inhibit HIV-1 Infection by Down-regulating Rho Activity

  2004cited by this paper
• Statin-induced immunomodulatory effects on human T cells in vivo.

  2004cited by this paper
• Statin Compounds Reduce Human Immunodeficiency Virus Type 1 Replication by Preventing the Interaction between Virion-Associated Host Intercellular Adhesion Molecule 1 and Its Natural Cell Surface Ligand LFA-1

  2004cited by this paper
• Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection

  2004cited by this paper
• Efficacy of an HIV prevention intervention for African American adolescent girls: a randomized controlled trial.

  2004cited by this paper
• Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART

  2003cited by this paper
• Attenuated T-Lymphocyte Response to HIV Therapy in Individuals Receiving HMG-CoA Reductase Inhibitors

  2003cited by this paper
• Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity

  2002cited by this paper
• Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.

  2002cited by this paper
• Lipid Rafts and HIV Pathogenesis: Host Membrane Cholesterol Is Required for Infection by HIV Type 1

  2001cited by this paper
• A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

  1997cited by this paper
• Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium.

  1994cited by this paper
• Regression analysis for correlated data.

  1993cited by this paper
• An overview of methods for the analysis of longitudinal data.

  1992cited by this paper

• No citing papers are available for this paper.